GW Pharmaceuticals plc announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Catherine Mackey, Alicia Secor and Lord William Waldegrave are joining the Board of Directors from December 21, 2017. Dr. Mackey is an experienced corporate executive, director and advisor with over thirty years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is currently Chief Executive Officer of CYPrus Therapeutics Inc. and Chairman of the Board of Cour Pharmaceutical Development. In addition, she serves on the Board of Directors of Rady Children’s Hospital and as an advisor to several companies. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide R&D and Director, of Pfizer’s La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer’s main pharmaceutical research and development sites with over 1,000 employees and a robust drug pipeline. Alicia Secor is currently President and Chief Executive Officer of Juniper Pharmaceuticals. Ms. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas. Ms. Secor was previously Chief Commercial Officer at Zafgen Inc. and Senior Vice President and Chief Operating Officer at Synageva BioPharma Corp. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University.